chartexchange

Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion Protein

GlobeNewswire Inc. | Oct 30, 2026 2:04 AM EDT

Dual-Target Approach Designed to Modulate Both Innate and Adaptive Immunity Advances Into Clinical Evaluation in Patients With SLE Dual-Target Approach Designed to Modulate Both Innate and Adaptive Immunity Advances Into Clinical Evaluation in Patients With SLE

Read original article